Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
13
07
2023
accepted:
09
10
2023
revised:
02
11
2023
medline:
6
11
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy. We expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA. Dogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05). These verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.
Sections du résumé
BACKGROUND
BACKGROUND
Cystic echinococcosis (CE) is caused by the infection of Echinococcus granulosus sensu lato (E. granulosus s.l.), one of the most harmful zoonotic helminths worldwide. Infected dogs are the major source of CE transmission. While praziquantel-based deworming is a main measure employed to control dog infections, its efficacy is at times compromised by the persistent high rate of dog re-infection and the copious discharge of E. granulosus eggs into the environment. Therefore, the dog vaccine is a welcome development, as it offers a substantial reduction in the biomass of E. granulosus. This study aimed to use previous insights into E. granulosus functional genes to further assess the protective efficacy of six recombinant proteins in dogs using a two-time injection vaccination strategy.
METHODS
METHODS
We expressed and combined recombinant E. granulosus triosephosphate isomerase (rEgTIM) with annexin B3 (rEgANXB3), adenylate kinase 1 (rEgADK1) with Echinococcus protoscolex calcium binding protein 1 (rEgEPC1), and fatty acid-binding protein (rEgFABP) with paramyosin (rEgA31). Beagle dogs received two subcutaneous vaccinations mixed with Quil-A adjuvant, and subsequently orally challenged with protoscoleces two weeks after booster vaccination. All dogs were sacrificed for counting and measuring E. granulosus tapeworms at 28 days post-infection, and the level of serum IgG was detected by ELISA.
RESULTS
RESULTS
Dogs vaccinated with rEgTIM&rEgANXB3, rEgADK1&rEgEPC1, and rEgFABP-EgA31 protein groups exhibited significant protectiveness, with a worm reduction rate of 71%, 57%, and 67%, respectively, compared to the control group (P < 0.05). Additionally, the vaccinated groups exhibited an inhibition of worm growth, as evidenced by a reduction in body length and width (P < 0.05). Furthermore, the level of IgG in the vaccinated dogs was significantly higher than that of the control dogs (P < 0.05).
CONCLUSION
CONCLUSIONS
These verified candidates may be promising vaccines for the prevention of E. granulosus infection in dogs following two injections. The rEgTIM&rEgANXB3 co-administrated vaccine underscored the potential for the highest protective efficacy and superior protection stability for controlling E. granulosus infections in dogs.
Identifiants
pubmed: 37871121
doi: 10.1371/journal.pntd.0011709
pii: PNTD-D-23-00881
pmc: PMC10621941
doi:
Substances chimiques
Vaccines, Synthetic
0
Recombinant Proteins
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011709Informations de copyright
Copyright: © 2023 Shao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Trends Parasitol. 2009 Feb;25(2):57-8
pubmed: 19084478
Zoonoses Public Health. 2019 Dec;66(8):889-899
pubmed: 31529690
Parasit Vectors. 2021 Sep 23;14(1):489
pubmed: 34556147
Am J Trop Med Hyg. 2016 Mar;94(3):626-33
pubmed: 26787154
J Infect Dis. 2006 Oct 1;194(7):966-74
pubmed: 16960785
Adv Parasitol. 2019;104:165-246
pubmed: 31030769
Curr Protein Pept Sci. 2019;20(4):304-315
pubmed: 30370845
Transbound Emerg Dis. 2022 Sep;69(5):e1382-e1392
pubmed: 35139582
Parasite Immunol. 2006 Jul;28(7):295-303
pubmed: 16842266
Parasitol Res. 2018 Oct;117(10):3169-3176
pubmed: 30027383
Vet Parasitol. 2022 Dec;312:109815
pubmed: 36335831
PLoS Negl Trop Dis. 2022 Oct 14;16(10):e0010540
pubmed: 36240240
Acta Trop. 2015 May;145:1-7
pubmed: 25661801
Res Vet Sci. 2021 Mar;135:517-522
pubmed: 33246571
PLoS Negl Trop Dis. 2008 Jan 16;2(1):e125
pubmed: 18235847
Infect Dis Poverty. 2018 Jun 13;7(1):61
pubmed: 29895318
Front Microbiol. 2020 Apr 22;11:729
pubmed: 32390980
Rev Panam Salud Publica. 2012 Jan;31(1):81-7
pubmed: 22427169
Parasitol Res. 2017 Jun;116(6):1665-1674
pubmed: 28455627
PLoS Negl Trop Dis. 2015 Oct 30;9(10):e0004134
pubmed: 26517877
Protein Sci. 2006 Jun;15(6):1489-93
pubmed: 16672241
Vet Immunol Immunopathol. 2000 May 23;74(3-4):195-208
pubmed: 10802288
Infect Dis Poverty. 2021 Mar 24;10(1):38
pubmed: 33762009
PLoS Negl Trop Dis. 2021 Mar 8;15(3):e0009253
pubmed: 33684115
Transbound Emerg Dis. 2021 May;68(3):1080-1096
pubmed: 32762075
J Proteomics. 2013 Jun 12;84:158-75
pubmed: 23603110
Nat Med. 2013 Dec;19(12):1597-608
pubmed: 24309663
Parasit Vectors. 2021 Feb 8;14(1):103
pubmed: 33557917
Nat Genet. 2013 Oct;45(10):1168-75
pubmed: 24013640
Vet Parasitol. 2003 Jul 25;115(2):83-123
pubmed: 12878418
Infect Dis Poverty. 2022 May 26;11(1):59
pubmed: 35619124
Clin Microbiol Rev. 2019 Feb 13;32(2):
pubmed: 30760475
Parasitol Res. 2023 Jul;122(7):1557-1565
pubmed: 37148368
Acta Trop. 2019 Mar;191:1-7
pubmed: 30576624
Adv Parasitol. 2017;96:55-158
pubmed: 28212791
Front Cell Infect Microbiol. 2020 Apr 30;10:177
pubmed: 32426296